Azitra (AZTR) Total Current Liabilities (2022 - 2026)
Azitra's (AZTR) quarterly Total Current Liabilities came in at $1.5 million in Q1 2026, up 21.04% YoY from $1.3 million in Q1 2025, and up 45.12% on a QoQ basis from $1.1 million in Q4 2025.
Azitra (AZTR) Total Current Liabilities (2022 - 2026) Analysis & Trends
Azitra (AZTR) has 5 years of Total Current Liabilities data on file, last reported at $1.5 million in Q1 2026.
- Quarterly Total Current Liabilities rose 21.04% year-over-year to $1.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.5 million (up 21.04% YoY) and the FY2025 annual result came in at $1.1 million, down 22.38% from the prior year.
- Total Current Liabilities rose to $1.5 million in Q1 2026, from $1.1 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $2.2 million in Q4 2022 to a low of $1.1 million in Q4 2025.
- A 5-year average of $1.5 million and a median of $1.5 million in 2023 frame the typical range for Total Current Liabilities.
- Annual changes were most pronounced in 2023 — Total Current Liabilities fell 27.85% — and 2025, when it soared 32.03%.
- Tracing AZTR's Total Current Liabilities over 5 years: stood at $2.2 million in 2022, then fell by 27.85% to $1.6 million in 2023, then fell by 14.18% to $1.4 million in 2024, then decreased by 22.38% to $1.1 million in 2025, then soared by 45.12% to $1.5 million in 2026.
- The last three Total Current Liabilities figures came in at $1.5 million (Q1 2026), $1.1 million (Q4 2025), and $1.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.51 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 438.74 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 630.93 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 2.49 Bn |
| 10 | Azitra | 2.44 Mn | 2.44 Mn | - | 1.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.53 Mn |
| Mar 31, 2026 | 1.55 Mn |
| Dec 31, 2025 | 1.07 Mn |
| Sep 30, 2025 | 1.81 Mn |
| Jun 30, 2025 | 1.45 Mn |
| Mar 31, 2025 | 1.28 Mn |
| Dec 31, 2024 | 1.38 Mn |
| Sep 30, 2024 | 1.37 Mn |
| Jun 30, 2024 | 1.74 Mn |
| Mar 31, 2024 | 1.26 Mn |
| Dec 31, 2023 | 1.60 Mn |
| Sep 30, 2023 | 1.45 Mn |
| Jun 30, 2023 | 1.74 Mn |
| Dec 31, 2022 | 2.22 Mn |